Kitov Pharmaceuticals Holdings Ltd. announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for KIT-302, its lead drug candidate. KIT-302 is a patented combination of celecoxib and amlodipine, and is intended to treat osteoarthritis pain and hypertension simultaneously. The company expects that within 60 days the FDA will determine whether the NDA is complete and acceptable for filing.